RE 2047

Drug Profile

RE 2047

Latest Information Update: 01 Sep 1998

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antiplatelets; Ischaemic heart disorder therapies; Small molecules; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Coronary thrombosis; Thrombosis

Most Recent Events

  • 01 Sep 1998 No-Development-Reported for Thrombosis in Germany (Unknown route)
  • 01 Sep 1998 No-Development-Reported for Coronary thrombosis in Germany (Unknown route)
  • 23 Jun 1995 An in vitro study has been added to the Thromboses pharmacodynamic section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top